Go to Top
INVENTOR LOGIN

Details

Project TitleBlood Biomarker for Early Blood Brain Barrier Disruption in Ischemic Stroke
Track Code2012-035
Short Description

Blood brain barrier (BBB) disruption is a hypothesized precursor to ICH. Studies have shown an intriguing phenomenon that ischemic brain regions with compromised BBB at the time of tPA administration

Abstract

Blood brain barrier (BBB) disruption is a hypothesized precursor to ICH. Studies have shown an intriguing phenomenon that ischemic brain regions with compromised BBB at the time of tPA administration are at high risk of intracerebral bleeding. As thus, early ischemic BBB damage appears to be a key factor to determine whether ischemic brain tissue can safely withstand a return of blood flow and is increasingly considered a promising pretreatment predictor for post-thrombolysis ICH. Researchers at the University of New Mexico have used this concept to develop a rapid and reliable blood-based indicator for predicting post-thrombolysis ICH. This technology detects early ischemic BBB damage thus allowing physicians to administer tPA treatment while understanding the patient's risk for symptomatic ICH.

 
Tagsbiomarker, neuro, stroke
 
Posted DateNov 5, 2014

Researcher

Name
Graham Timmins
Ke Jian Liu
Wenlan Liu
Rong Pan

Manager

Name
Jovan Heusser

Background

Stroke is the third leading cause of death and the leading cause of adult disability in developed countries. In the United States, approximately 795,000 people experience a new or recurrent stroke each year. Intravenous thrombolysis with tissue plasminogen activator (tPA) remains the only FDA-approved therapy for acute ischemic stroke.  However, only a small fraction of potentially eligible stroke patients in the United States are receiving tPA therapy, with an estimated rate of tPA use of 1.8% to 2.1% in ischemic stroke patients. One barrier to widespread implementation of acute stroke thrombolysis is the fear of symptomatic intracerebral hemorrhage (ICH) which has a 50% mortality rate. Evidence from randomized clinical trials and subsequent clinical experience clearly demonstrates that tPA thrombolysis presents real safety concerns due to a 10-fold increase in the incidence of symptomatic ICH. If a method for identifying patients who are at low risk of developing symptomatic ICH could be developed, more stroke patients could benefit from tPA therapy.

Technology Description

Blood brain barrier (BBB) disruption is a hypothesized precursor to ICH. Studies have shown an intriguing phenomenon that ischemic brain regions with compromised BBB at the time of tPA administration are at high risk of intracerebral bleeding. As thus, early ischemic BBB damage appears to be a key factor to determine whether ischemic brain tissue can safely withstand a return of blood flow and is increasingly considered a promising pretreatment predictor for post-thrombolysis ICH. Researchers at the University of New Mexico have used this concept to develop a rapid and reliable blood-based indicator for predicting post-thrombolysis ICH. This technology has the potential to clinically detect early ischemic BBB damage thus allowing physicians to administer tPA treatment while understanding the patient’s risk for symptomatic ICH.

Advantages/Applications

  • Provides an early diagnostic indicator to guide acute stroke therapy
  • Allows for more patients to be safely treated with tPA
  • Large market (combined US & EU market size of $12.56 billion according to AcquiSci)

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.

Files

File Name Description
US 2017/0199205 A1 Published Patent Application None Download
9,599,625 Issued Patent None Download
9,606,129 Issued Patent None Download

Intellectual Property

Patent Number Issue Date Type Country of Filing
9,606,129 Mar 28, 2017 Utility United States
9,599,625 Mar 21, 2017 Cont-in-Part United States